AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time, setting up regulatory filings.

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

T-DXd monotherapy and T-DXd plus pertuzumab continue to show robust efficacy in HER2-positive metastatic breast cancer.

The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan ...

The American Association for Cancer Research has called on Congress "to summarily reject" the Trump administration's 2026 ...

Greenwich LifeSciences showed initial HER2 data, yet faces funding issues and competitive pressure in a fast-moving field. See why GLSI stock is a sell.

Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...